Welcome to our dedicated page for Acutus Medical news (Ticker: AFIB), a resource for investors and traders seeking the latest updates and insights on Acutus Medical stock.
Acutus Medical, Inc. (OTC: AFIB) drives innovation in cardiac electrophysiology through its specialized left-heart access devices and strategic partnerships. This page serves as the definitive source for verified news and press releases directly from the company.
Investors and healthcare professionals will find timely updates on manufacturing agreements, product developments, and operational milestones. Our curated collection ensures access to essential information about AFIB's evidence-based solutions for complex arrhythmias, including its collaboration with Medtronic.
Key updates cover regulatory progress, clinical advancements, and financial developments while maintaining compliance with disclosure standards. All content undergoes rigorous verification to provide reliable insights into the company's focused electrophysiology strategy.
Bookmark this page to stay informed about Acutus Medical's latest achievements in medical device innovation and operational efficiency improvements. Check regularly for authoritative updates from the source.
Acutus Medical, Inc. (Nasdaq: AFIB) announced the submission of pivotal clinical data from the AcQForce Flutter trial to the FDA for its AcQBlate Force Sensing Ablation Catheter and System. This submission is a major milestone as catheter ablation for right atrial flutter constitutes about 30% of ablations in the U.S., projected to reach 200,000 by 2025. The trial showed successful acute procedural success with no serious adverse events reported. The full data will be presented at the AF Symposium in February 2023, reinforcing Acutus's growth strategy.
On October 1, 2022, Acutus Medical (Nasdaq: AFIB) granted 11,500 restricted stock units (RSUs) to three newly hired employees as part of its 2022 Inducement Equity Incentive Plan. The grants, approved by the Compensation Committee, are intended as a material inducement for employment. Each employee’s RSUs will vest one-fourth yearly and fully vest on the fourth anniversary, contingent on their continued employment. Acutus is focused on enhancing arrhythmia diagnosis and treatment through innovative products and technologies.
Acutus Medical announced on September 1, 2022, the approval of an equity award under its 2022 Inducement Equity Incentive Plan. This award was granted to a new employee as a material inducement for employment. The employee will receive 2,000 restricted stock units (RSUs), with 25% vesting annually over four years, contingent upon continued employment. Acutus, based in Carlsbad, California, focuses on enhancing cardiac arrhythmia diagnosis and treatment through innovative technologies and partnerships.
Acutus Medical, Inc. (AFIB) reported Q2 2022 revenue of $4.1 million, a 13% decrease from $4.7 million in Q2 2021, attributed to a drop in capital and disposable revenue. Global mapping procedures increased by 20% year-over-year. The company completed a portfolio sale to Medtronic and debt refinancing to strengthen financials. While GAAP net income improved to $5.7 million from a loss of $28.7 million last year, non-GAAP net loss was $26.2 million. Cash resources stood at $93.1 million as of June 30, 2022.
Acutus Medical (Nasdaq: AFIB), a company focused on arrhythmia management, announced the grant of 17,500 restricted stock units (RSUs) to five new employees as part of its 2022 Inducement Equity Incentive Plan. The awards, approved by the company's Compensation Committee, serve as a material inducement for employment and will vest over four years, contingent on continued employment. This initiative aligns with Acutus' commitment to enhancing the diagnosis and treatment of cardiac arrhythmias, supported by its innovative product portfolio and global partnerships.
Acutus Medical (Nasdaq: AFIB) plans to release its Q2 2022 financial results on August 11, 2022.
A conference call and webcast will follow at 1:30 p.m. Pacific Time to discuss the results and recent highlights. Participants can register in advance for the call and will receive dial-in numbers and a unique PIN via email.
Acutus focuses on improving cardiac arrhythmias diagnosis and treatment through innovative products and technologies, contributing to more efficient patient care.
Acutus Medical announced the approval of its AcQMap High Resolution Imaging and Mapping System and AcQMap 3D Imaging and Mapping Catheter for use in Japan, a key growth market. The electrophysiology (EP) mapping and ablation market in Japan is projected to exceed $1.4 billion in 2022, with expectations to grow to $1.8 billion by 2025. Acutus, in partnership with BIOTRONIK, is set to enhance arrhythmia diagnosis and treatment through its innovative, non-contact technology.
Acutus Medical, Inc. (Nasdaq: AFIB) announced the appointment of David Roman as President and CEO, effective immediately. Roman, previously interim CEO and CFO, aims to enhance operational strategies and financial performance. The company reported preliminary second quarter revenues of approximately $4.0-$4.1 million, compared to $4.7 million in Q2 2021. Notably, there was a significant cash burn decline compared to Q1 2022. The full financial results will be disclosed in August, along with updates on operational improvements.
On July 1, 2022, Acutus Medical (Nasdaq: AFIB) granted a total of 6,000 restricted stock units (RSUs) to two new employees as part of its 2022 Inducement Equity Incentive Plan. This award is intended to incentivize their employment and will vest yearly over four years, contingent upon continued employment. Acutus, based in Carlsbad, California, specializes in arrhythmia management, aiming to enhance diagnosis and treatment of cardiac arrhythmias with a comprehensive array of electrophysiology products and technologies.
Acutus Medical completed the first closing of its left-heart access portfolio sale to Medtronic for $50 million on June 30, 2022. This includes the AcQCross™ and AcQGuide® product lines, with potential contingent payments of up to $37 million based on regulatory milestones. Additionally, the company secured a $35 million debt facility from Deerfield Management to refinance existing debts, maturing in June 2027. Acutus aims to enhance its financial position, enabling investments in product development and market strategies.
